Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 15



CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-35837



Tetraphase Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)




480 Arsenal Way
Watertown, Massachusetts 02472
(617) 715-3600
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, Par Value $0.001 Per Share
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)




Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
 
Rule 12g-4(a)(1)
 
 
 
Rule 12g-4(a)(2)
 
 
 
Rule 12h-3(b)(1)(i)
 
 
 
Rule 12h-3(b)(1)(ii)
 
 
 
Rule 15d-6
 
 
 
Rule 15d-22(b)
 

Approximate number of holders of record as of the certification or notice date: One (1)

Pursuant to the requirements of the Securities Exchange Act of 1934, Tetraphase Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.






 
 
 
TETRAPHASE PHARMACEUTICALS, INC.

 
 
 
 
Date:
August 7, 2020
By:
/s/    Larry Edwards
 
 
 
Larry Edwards
 
 
 
President and Chief Executive Officer